Published in final edited form as:

Biometals. 2011 June ; 24(3): 455–466. doi:10.1007/s10534-011-9430-9.

Systems biology approach to Wilson's disease

Jason L. Burkhead

University of Alaska Anchorage, Anchorage, AK 99508, USA

Lawrence W. Gray and Svetlana Lutsenko

Department of Physiology, Johns Hopkins University, Baltimore, MD 21230, USA

Abstract

Wilson's disease (WD) is a severe disorder of copper misbalance, which manifests with a wide spectrum of liver pathology and/or neurologic and psychiatric symptoms. WD is caused by mutations in a gene encoding a copper-transporting ATPase ATP7B and is accompanied by accumulation of copper in tissues, especially in the liver. Copper-chelation therapy is available for treatment of WD symptoms and is often successful, however, significant challenges remain with respect to timely diagnostics and treatment of the disease. The lack of genotype-phenotype correlation remains unexplained, the causes of fulminant liver failure are not known, and the treatment of neurologic symptoms is only partially successful, underscoring the need for better understanding of WD mechanisms and factors that influence disease manifestations. Recent gene and protein profiling studies in animal models of WD began to uncover cellular processes that are primarily affected by copper accumulation in the liver. The results of such studies, summarized in this review, revealed new molecular players and pathways (cell cycle and cholesterol metabolism, mRNA splicing and nuclear receptor signaling) linked to copper misbalance. A systems biology approach promises to generate a comprehensive view of WD onset and progression, thus helping with a more fine-tune treatment and monitoring of the disorder.

Keywords

Wilson's disease; Array; Copper; LEC rat; ATP7B; Proteomics

Wilson's disease (WD) is caused by mutations in the copper-transporting ATPase ATP7B

WD is an autosomal recessive disorder caused by mutations in the gene *ATP7B* that encodes an ATP-driven copper transporter of the same name (Das and Ray 2006). In a healthy organism, ATP7B is expressed in various tissues, including liver, central nervous system, kidney, mammary gland, and others (Lutsenko et al. 2007). The major physiologic role of ATP7B is in the liver, a key homeostatic organ for copper metabolism. In hepatocytes, ATP7B transports copper from the cytosol into the lumen of the *trans*-Golgi network (TGN), where copper is post-translationally incorporated into secreted copper-dependent enzymes, such as ceruloplasmin. In addition, ATP7B maintains copper levels in the cytosol. When cytosolic copper exceeds a certain threshold, ATP7B traffics towards the canalicular membrane and sequesters excess copper into vesicles, which subsequently fuse with the canalicular membrane excreting excess copper into the bile (Bartee and Lutsenko 2007).

In WD, ATP7B expression, function, and/or intracellular targeting are disrupted by mutations. As a result, copper delivery to the TGN and copper excretion are both impaired, and copper accumulates to very high levels. It is thought that a tissue's inability to adequately protect itself from excess of redox active copper causes the development of WD pathology (Ferenci 2005). Recent systematic analysis of genomic and proteomic changes also show that in addition to well-described damaging effects of high copper on DNA, proteins, and lipids, copper misbalance triggers a series of more specific metabolic responses that are likely to significantly influence pathology development. The results of these studies are summarized in this review.

Phenotypic variability and a lack of genotype-phenotype correlations in WD

Since the initial discovery of *ATP7B* (Bull et al. 1993; Tanzi et al. 1993) and first characterization of its gene structure (Petrukhin et al. 1994), over 380 mutations in this gene have been identified in WD patients world-wide (see WD mutation database <http://www.wilsonsdisease.med.ualberta.ca/database.asp>). Most of the WD mutations result in a single base-pair substitution replacing an amino-acid (missense mutations). However, nonsense, insertion, deletion and splice site mutations, which more drastically affect transcript and protein structure, have also been reported (Okada et al. 2010; Wilson et al. 2009; Kusuda et al. 2000). Although none of the WD mutations are predominant, several mutations show higher frequency in different world populations (Ferenci 2006). The best characterized H1069Q mutation is a prevalent mutation in Caucasian population of European origin (Vrabelova et al. 2005), including Lithuanian (Kucinskas et al. 2008), Czech (Vrabelova et al. 2005) Hungarian (Folhoffer et al. 2007), German (Huster et al. 2004) and other groups. In contrast, the R778L mutation is predominant among Korean (Kusuda et al. 2000; Park et al. 2009), Chinese (Mak et al. 2008), and Japanese (Kusuda et al. 2000) patients. Neither H1069Q nor R778L are common in India, where mutation resulting in the replacement of Cys271 with a Stop codon appears to be among the most frequent (Gupta et al. 2005). The carriers' rate was estimated to be highest among Asians (1:51) followed by African Americans and Caucasians (both groups at 1:87).

Significant effort in examining genotype-phenotype correlations revealed some trends; for example, patients with protein truncating mutations have in general earlier onset of the disease (Merle et al. 2010), and the early onset and predominantly hepatic course was reported for R778L mutation (Wu et al. 2001). In contrast, the H1069Q substitution was suggested to be associated with a late on-set and neurological presentation (Stapelbroek et al. 2004). However, other studies comparing various mutations showed no correlations with a phenotype (Nicastro et al. 2009; Hermann et al. 2002). Furthermore, markedly different disease manifestations (fulminant liver failure versus a pre-symptomatic liver disease) have recently been reported for genetically identical twins homozygous for H1069Q mutation (Kegley et al. 2010; Czlonkowska et al. 2009). Overall, there has been a growing appreciation that epigenetic/environmental and/or dietary factors may play a very important role in modulating the WD phenotype. Little is known about such factors. As we illustrate in this review, a systems biology approach promises to facilitate their discovery.

Molecular mechanism of WD is not well understood

Currently, the generally cited mechanism of pathology development in Wilson's disease involves oxidative damage due to copper overload (Ferenci 2005). Generation of reactive oxygen species (ROS) as well as lipid oxidation and DNA damage has been detected in the WD liver, particularly at the advanced stages of the disease (Yasuda et al. 2006; Nair et al. 1998; Hayashi et al. 2006). At the same time, radical-mediated damage alone does not explain the lack of genotype-phenotype correlations, the variability of symptoms even

among siblings, and worsening neurologic symptoms upon treatment with copper chelators. Studies in bacteria suggest that Cu(I) can also disrupt metabolic processes by binding to the coordinating sulfur atoms of Fe/S clusters, displacing iron and thus inhibiting the cluster containing enzymes (Macomber and Imlay 2009). Recent studies using animal models of WD uncovered additional players and new pathways that can contribute to pathology development. Although such studies are still very limited, the emerging data focus our attention on the cellular processes, the importance of which for WD has not been previously appreciated (see below).

The age of WD onset varies significantly; however, the disease typically presents in children and young adults. Although copper is always elevated in the WD liver, major disease manifestations vary, and either neurologic or hepatic phenotype may dominate. In the liver, copper overload triggers development of hepatitis, cirrhosis, which may progress to liver failure (Huster 2010). In the brain, globus pallidus, putamen, thalamus, mesencephalon, pons, and corpus collosum are most affected (Trocello et al. 2010). The development of neuropsychiatric symptoms (Involuntary movements, ataxia, depression) usually occurs in older patients and is thought to be secondary to liver malfunction. This view is probably an over-simplification, because ATP7B is expressed in various regions of the brain (Choi and Zheng 2009; Platonova 2005; Ahmed et al. 2005; Barnes et al. 2005) and its inactivation is likely to directly alter the CNS copper metabolism.

The molecular mechanisms behind WD phenotypic variability are not known. Recent proteomics studies in the *Atp7b*^{-/-} liver identified molecules altered in response to copper accumulation, which have well-established roles in CNS physiology (see below). Thus, it is possible that the molecular machinery responding to copper levels in the brain is similar to one in the liver, and the extent of disease manifestation in different organs depends on a tissue-specific modulation of this machinery in response to overall metabolic state of the organism.

Animal models of Wilson's disease

Several rodent models of Wilson's disease have been described (Table 1). Toxic milk mice (*tx* mice) is an inbred strain with a Met1386Val mutation within the copper translocation pathway of ATP7B (Theophilos et al. 1996). This mutation does not disrupt the ATP7B biosynthesis, but markedly decreases its transport activity (Voskoboinik et al. 2001) and prevents copper-dependent trafficking of the transporter from Golgi to vesicles (La Fontaine et al. 2001). In the *tx* animals, copper concentration is increased in the liver, spleen, kidney and the brain (Allen et al. 2006). Copper accumulation is associated with morphologic changes in hepatic mitochondria, endoplasmic reticulum, and nuclei as well as accumulation of microvesicular lipid droplets (Biempica et al. 1988). An alteration of mitochondrial enzyme function in animals older than 3 months also occurs (Roberts et al. 2008). The detailed protein or mRNA profiling has not been done for this animal model.

A different variant of the *tx* mice originates from the C3H/HeJ strain bred at the Jackson Laboratory (hence the name, *txJ*). The *txJ* mice contain the Gly712Asp substitution at the cytosolic end of the second transmembrane segment of ATP7B (Coronado et al. 2001). In addition, the *Atp7b* gene of *txJ* mice has nucleotide changes within the exon 2 that produce the Lys107Ser and His108Ala substitutions, which are thought to be polymorphisms. Adult homozygous *txJ* mice accumulate copper and develop cirrhosis, whereas infant mice are copper deficient and display increased mortality. This animal model is relatively recent and remains to be fully characterized. Interestingly, crossing the *txJ* mice with the transgenic CRND8 amyloid precursor protein mice decreases the number of plaques and increases survival compared to the latter (Phinney et al. 2003).

Most of the studies dissecting the mechanism of WD pathology have been done using Long-Evans Cinnamon (LEC) rats and, more recently, *Atp7b*^{-/-} mice. The LEC rats are an inbred strain, which has a large deletion in the 3' region of the *Atp7b* gene that abrogates protein production (Levy et al. 2007; Muramatsu et al. 1995). The *Atp7b*^{-/-} mice are genetically engineered whole-body knockouts maintained on a hybrid C57BLx129S6/SvEv background (Buiakova et al. 1999). In these mice, the insertion of multiple stop codons in exon 2 completely abolishes protein synthesis (Buiakova et al. 1999), similarly to LEC rats. As expected for human WD, the LEC rats and *Atp7b*^{-/-} mice accumulate copper in the liver, fail to incorporate copper into a copper-dependent enzyme ceruloplasmin (produced by the liver), and develop marked hepatic pathology. At the later stages of the disease, LEC rats develop hepatocellular carcinoma (Marquez et al. 2007), whereas old *Atp7b*^{-/-} animals do not have hepatocellular carcinoma, but show marked proliferation and tumor development in bile ducts (Huster et al. 2006).

Pathology development and corresponding changes in liver transcriptome

Although some aspects of pathology differ between rodent strains as well as between human and murine WD, the general course of liver disease is similar for these species. Specifically, copper accumulation occurs rapidly and precedes visible pathology development. In the 6 weeks old LEC rats and *Atp7b*^{-/-} mice hepatic copper is already high, whereas liver histology is fairly normal (Huster et al. 2006; Kasai et al. 1990). Subsequently, at around 8–9 weeks the increase in the size of hepatocytes and nuclei becomes apparent (Huster et al. 2006) and, in rats, there is an onset of jaundice (Kasai et al. 1990). In a period from 12 to 20 weeks, the disease is pronounced with a significant inflammation, necrosis and diminished liver function. 30–40% LEC rats die at the age of 4 months, whereas surviving rats develop tumors along with regenerative nodules. *Atp7b*^{-/-} mice do not show increased mortality even at the height of the disease; at 30–35 weeks their liver begins to regenerate along with a marked proliferation and tumor development in bile ducts. It should be noted that the precise age at which different symptoms manifest may differ between animals bred in different laboratories/countries, which may reflect local conditions in animal housing, water supply, mode of breeding. Defining the stage of the liver disease by physiologic/biochemical parameters (rather than age) is likely to provide a more consistent picture when the results from different laboratories are compared.

Several groups have investigated molecular mechanisms behind copper-induced pathology by characterizing changes in hepatic mRNA profiles (Ralle et al. 2010; Klein et al. 2003; Tsubota et al. 2010; Huster et al. 2007; Marquez-Quinones et al. 2007). The precise gene-to-gene comparison of the results is difficult, because studies used different array platforms and the age of animals and the functional state of their liver did not match exactly. Nevertheless, overall trends (i.e., the major biological processes affected by copper overload) can be identified and compared. In order to make such comparisons with a minimal bias, we analyzed with the same GeneSifter software the mRNA array data that were relatively similar (Klein et al. 2003; Tsubota et al. 2010; Marquez-Quinones et al. 2007). We specifically focused on the earlier stages of pathology development (i.e., when pathology is not yet apparent or mild) to identify initial, and presumably more specific, effects of copper and to minimize differences between strains that become more apparent with age. The results are summarized in Tables 2 and 3. The data from Tsubota et al. represent changes in the 26 weeks LEC rats compared to 4 weeks old LEC rats (i.e., diseased state versus non-diseased state, whereas the data from Huster et al. show changes in the 6 week-old *Atp7b*^{-/-} compared to the wt mice. These two sets of data are easier to compare because in both studies the entire transcriptome was probed, whereas Klein et al. (2003) used a more limited set of probes on a toxicology specialized Affymetrix RTU34 oligonucleotide array covering

1031 genes (In Tables 2 and 3, we show comparisons of data for 9 weeks to 6 weeks old LEC rats from this latter study).

It is apparent that common processes that accompany disease development in mice and the early-mid stage of disease in rats involve up-regulation of cell cycle and cell division (Table 2), whereas the most significantly down-regulated process is lipid metabolism (steroid metabolism and cholesterol metabolism, Table 3). In fact, in *Atp7b*^{-/-} mice the transcripts of genes involved in lipid metabolism remain down-regulated throughout the entire course of the disease (Ralle et al. 2010). These changes in the transcriptome are associated with metabolic changes, as demonstrated by the decreased levels of cholesterol in the liver and of VLDL cholesterol in a serum of *Atp7b*^{-/-} mice (Ralle et al. 2010; Huster et al. 2007). Recent studies in LEC rats also revealed significant lipid misbalance: the decrease in serum cholesterol and abnormalities in both circulating lipoprotein composition and size along with a significantly increased content of triglycerides, free cholesterol, and cholesteryl ester in the liver (Li et al. 2009). It is interesting that the down-regulation of genes associated with cholesterol biosynthesis was also observed in the liver of fish exposed to high copper (Santos et al. 2010), suggesting conservation of hepatic response to copper overload in low and high vertebrates.

Nuclear receptor signaling is significantly dysregulated in response to copper overload

Previous analysis of transcripts down-regulated in *Atp7b*^{-/-} mice identified SREBP-1, as a factor at the center of down-regulated network (Huster et al. 2006). However, the mRNA levels of SREBP-1 are also decreased (Huster et al. 2006), indicating that factors upstream of SREBP-1 may play important role in altering lipid metabolism. Analysis of down-regulated signaling pathways reveals significant involvement of LXR/RXR/FXR nuclear receptors in hepatocytes response to copper overload (Fig. 1). This observation is particularly interesting because of the dual role of LXR/RXR in lipid metabolism and inflammation (Zhao and Dahlman-Wright 2010; Morello et al. 2009). The LXR and RXR agonists, oxysterols and retinoic acid respectively, promote transcription of lipid metabolism related genes and inhibit the NF- κ B dependent activation of inflammatory mediators (Bensinger et al. 2008). Thus, down-regulation of the LXR/RXR signaling may account for the observed changes in lipid metabolism and liver inflammation in WD. Reciprocally, metabolic changes in *Atp7b*^{-/-} hepatocytes may trigger inflammatory response, which in turn would repress lipid metabolism through the LPS/IL-1 mediated Inhibition of RXR Function (LMIRF). For example, during inflammation RXRs may leave the nucleus, thus suppressing transcription of RXR controlled genes (Ghose et al. 2004).

Comparison of available datasets also show some differences. Inflammatory and oxidative stress signaling via IL-17 and NRF2, respectively, are among the down-regulated pathways in the 6 weeks old *Atp7b*^{-/-} mouse but not in the LEC rats (Fig. 1). This difference is likely due to a more advanced age of LEC animals, whose liver at 26 weeks does undergo inflammation. It would be important to compare younger LEC rats to determine if changes in lipid metabolism precede oxidative stress/inflammatory response as seen in the 6 week *Atp7b*^{-/-} mouse.

Additional information was revealed in the mRNA profiling studies where time-dependent progression of hepatitis in the LEC rat was monitored using animals treated with a copper-chelating drug D-penicillamine as a control (Marquez-Quinones et al. 2007). This study also included useful evaluation of liver morphology and function. Comparison to the chelator-treated rats (rather than LEC rats) is an interesting experimental design, because genetic background of animals in this experiment is the same (an important consideration) and

specific effects of copper are likely to be more clearly dissected. At the same time, if transcriptional changes occur in the control D-penicillamine-treated animals, such changes could be missed. Overall, the study has pointed to the upregulation of glutathione-S-transferase P (GSTP) as being characteristic for the stage of hepatitis associated with jaundice development. Among the annotated transcripts the majority (38 out of 59) belong to the “metabolism” category with the most affected metabolic processes being lipid biosynthesis and catabolism, alcohol metabolism and amino-acid biosynthesis (in addition to other less altered pathways) (Marquez-Quinones et al. 2007). Altogether, lipid metabolism is emerging as an important pathway to consider in WD pathology.

Studies in cultured cell lines identify stress-response genes

Another trend reported in the above study of LEC rats was upregulation of protein degradation machinery along with pathology progression (Marquez-Quinones et al. 2007). This observation resonates with the results of Muller and colleagues, who investigated response of cultured hepatocytes HepG2 to high copper load (Muller et al. 2007). HepG2 cells contain active ATP7B and therefore represent a model of acute copper toxicity rather than WD; nevertheless, some parallels in cell response to high copper may exist. The initial response of HepG2 cells to high copper involves upregulation of metallothionein (also seen in WD patients and in all animal models of WD), whereas longer exposure to copper induces transcripts for proteins involved in proteasomal degradation and oxidative stress response (Muller et al. 2007). In *Atp7b*^{-/-} mice, changes in the abundance of transcripts for proteasomal components and ubiquitinating enzymes are also seen (for example, ubiquitin specific protease Usp2 is down-regulated early in the disease, whereas the ubiquitin-conjugating enzyme E2 variant 2 is up at the later stage of the disease, our data) along with the upregulation of other soluble and membrane-bound proteases. It appears that the enhanced protein degradation may represent a general protective response of hepatocytes to a prolonged exposure to a very high copper.

Another response to a prolonged injury may involve activation of the NF- κ B signaling pathway. The upregulation of this pathway was observed in HepG2 cells in response to a 4 h treatment with 400 or 600 μ M copper (McElwee et al. 2009). How closely these conditions resemble WD remains to be determined. In WD liver, copper can be extremely high (reaching mM levels in the cytosol and nuclei (Ralle et al. 2010)), however such accumulation occurs gradually. Analysis of the *Atp7b*^{-/-} mRNA dataset at the early stage of the disease did not show the NF- κ B pathway as the most significantly upregulated (Fig. 2). Instead, CDKN1A, cyclin-dependent kinase inhibitor 1A, appears to play a prominent role. It should also be noted that the mRNA profiling of the entire liver does not discriminate between different cellular populations, and the contribution of cells other than hepatocytes (for example bile ducts' cells that eventually proliferate) to the network of upregulated genes cannot be excluded. At the same time, upregulated genes linked to NF- κ B are present in the early CDKN1A network (Fig. 2); thus more significant involvement of the NF- κ B signaling may take place at the later stage of the disease when copper levels exceed liver buffering capacity.

RNA processing machinery: a link between hepatic and neurologic symptoms in WD?

Analysis of the transcriptome offers a relatively quick way to generate useful insights into the physiological state of cells and tissue. The mRNA abundance suggests the amounts of corresponding proteins, however this information is indirect as the transcripts are one or more steps removed from key physiologic players: proteins and their metabolites. Consequently, proteomic studies, although technically more challenging, are gaining

momentum as the way to generate mechanistic insights into pathology development. Focus on the proteome of specific subcellular compartments can be particularly informative. Within the *Atp7b*^{-/-} hepatocytes, copper is distributed non-uniformly, and this distribution changes as disease progresses. At the early stage of pathology development the highest copper is preferentially elevated in the cytosol and nuclei (Huster et al. 2006; Ralle et al. 2010). Studies of copper-induced changes in the nuclear proteome of *Atp7b*^{-/-} mice revealed a remodeling of RNA processing machinery as a possible mechanistic link between copper accumulation in nuclei and changes in the liver transcriptome (Burkhead et al. 2010). It was also found that copper, although markedly elevated in *Atp7b*^{-/-} nuclei, did not induce large-scale displacement of other metals from the nucleus, suggesting a high buffering capacity of nuclei for metals. Similarly, global protein oxidation was not apparent as no change was seen in the levels of reduced thiols, protein nitration and protein glutathionylation. At the same time, the nuclear-localized Selenoprotein H (SelH) showed an increase in protein abundance (Burkhead et al. 2010). This increase in SelH, which has a glutathione reductase activity, may help to maintain the proper ratio of reduced and oxidized glutathione in the nucleus and may be part of the reason why the large-scale oxidation is not observed despite high copper levels.

The 2D-gel based proteomic analysis of isolated *Atp7b*^{-/-} nuclei yielded two key observations. First, it became apparent that changes in the abundance and modification are limited to a small set of nuclear proteins, only a few of which were abundant. Second, the most significant group of changed nuclear proteins was one associated with mRNA processing (Burkhead et al. 2010). Upon further analysis by semi-quantitative mass spectrometry, it was found that some of the alteration in the levels of RNA processing proteins could be due to their nucleocytoplasmic redistribution. Specifically, the *Atp7b*^{-/-} nuclei showed an increase in apparent retention of hnRNPs A2/B1, A3 and U, which form a multiprotein complex (Raju et al. 2008). HnRNP A2/B1 is a component of the spliceosome, a marker in hepatocellular carcinoma and other cancer (Raju et al. 2008; Cui et al. 2010; Wu et al. 2003; Peebles et al. 2007), and it functions in nucleocytoplasmic shuttling of mRNA (Munro et al. 1999). In *Atp7b*^{-/-} liver, distinct alternative splicing-derived variant of hnRNP A2/B1 is upregulated due to increased retention of exon 2 (Burkhead et al. 2010).

Alteration of RNA processing machinery is likely one of the mechanisms that drives the observed changes in the transcriptome. For example, the LDL receptor mRNA is down-regulated in *Atp7b*^{-/-} livers (Huster et al. 2007) as well as in LEC rats. The LDL receptor transcript can be destabilized by KH-type splicing regulatory protein (KSRP) and hnRNP I through the AU-rich elements in the 3'UTR (Li et al. 2009). Coincidentally, KSRP is altered in *Atp7b*^{-/-} livers (Huster et al. 2007; Burkhead et al. 2010), a finding that offers a potential link to the observed down-regulation of the LDL receptor mRNA. Similarly TDP-43 and hnRNP H1 (both changed in *Atp7b*^{-/-} nuclei compared to control) have roles in alternative splicing of apolipoprotein-AII (Mercado et al. 2005), another transcript altered in *Atp7b*^{-/-} livers.

The involvement of RNA processing machinery, particularly TDP-43 and hnRNP A2/B1, in cells' response to elevated may provide a molecular link between hepatic and neurologic symptoms in WD. Recent data suggest that TDP-43 can be found in the mRNA processing sites in neurons and may have an important role in neurodegenerative disorders (Casafont et al. 2009; King et al. 2010). In turn, hnRNP A2/B1 is well characterized in nucleocytoplasmic shuttling of myelin-basic protein (MBP), the most abundant protein component of the myelin sheath in the CNS (Hoek et al. 1998; Shan et al. 2000). It is tempting to speculate that copper-induced alteration of RNA processing machinery may be a contributing factor to pathways leading to neuronal degeneration in WD.

Conclusions

WD is a severe disorder of copper metabolism with a varied age of onset and diverse phenotypic manifestations. Implementation of new data-driven approaches promises to greatly facilitate understanding of WD pathology. The diversity of WD phenotype and complexity of symptoms in humans indicates that the inactivation of ATP7B in WD has far-reaching physiological consequences. The “omics” studies have identified new metabolic and signaling pathways associated with disease progression, such as lipid metabolism, cell cycle regulation, LXR/RXR and CDKN1A signaling and, mRNA splicing. The cellular pathways and physiologic processes that are particularly sensitive to copper overload are likely to contribute to pathology development in WD. The “omics” studies also raise new mechanistic questions about previously unknown roles for copper in normal human physiology. In a future, systems information may allow for more finetuned therapies of WD, particularly with respect to symptoms unresponsive to copper chelation.

Acknowledgments

This work was supported by National Institute of Health grants R21 DK075659 and P01 GM067166 to SL. JLB is supported the sub-award to P20RR016466-10; LG is a recipient of the NRSA fellowship F31DK084730-02.

References

- Ahmed S, Deng J, Borjigin J. A new strain of rat for functional analysis of PINA. *Brain Res Mol Brain Res*. 2005; 137(1–2):63–69. [PubMed: 15950762]
- Allen KJ, et al. Chronological changes in tissue copper, zinc and iron in the toxic milk mouse and effects of copper loading. *Biometals*. 2006; 19(5):555–564. [PubMed: 16937262]
- Barnes N, Tsivkovskii R, Tsivkovskaia N, Lutsenko S. The copper-transporting ATPases, Menkes and Wilson disease proteins, have distinct roles in adult and developing cerebellum. *J Biol Chem*. 2005; 280(10):9640–9645. [PubMed: 15634671]
- Bartee MY, Lutsenko S. Hepatic copper-transporting ATPase ATP7B: function and inactivation at the molecular and cellular level. *Biometals*. 2007; 20(3–4):627–637. [PubMed: 17268820]
- Bensinger SJ, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. *Cell*. 2008; 134(1):97–111. [PubMed: 18614014]
- Biempica L, Rauch H, Quintana N, Sternlieb I. Morphologic and chemical studies on a murine mutation (toxic milk mice) resulting in hepatic copper toxicosis. *Lab Invest*. 1988; 59(4):500–508. [PubMed: 2845190]
- Buiakova OI, et al. Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. *Hum Mol Genet*. 1999; 8(9):1665–1671. [PubMed: 10441329]
- Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. *Nat Genet*. 1993; 5(4):327–337. [PubMed: 8298639]
- Burkhead JL, Ralle M, Wilmarth P, David L, Lutsenko S. Elevated copper remodels hepatic RNA processing machinery in the mouse model of Wilson’s disease. *J Mol Biol*. 2010; 406(1):44–58. [PubMed: 21146535]
- Casafont I, Bengoechea R, Tapia O, Berciano MT, Lafarga M. TDP-43 localizes in mRNA transcription and processing sites in mammalian neurons. *J Struct Biol*. 2009; 167:235–241. [PubMed: 19539030]
- Choi BS, Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. *Brain Res*. 2009; 1248:14–21. [PubMed: 19014916]
- Coronado V, Nanji M, Cox DW. The Jackson toxic milk mouse as a model for copper loading. *Mamm Genome*. 2001; 12(10):793–795. [PubMed: 11668395]
- Cui H, Wu F, Sun Y, Fan G, Wang Q. Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma. *BMC Cancer*. 2010; 10:356. [PubMed: 20604928]

- Czlonkowska A, Gromadzka G, Chabik G. Monozygotic female twins discordant for phenotype of Wilson's disease. *Mov Disord.* 2009; 24(7):1066–1069. [PubMed: 19306278]
- Das SK, Ray K. Wilson's disease: an update. *Nat Clin Pract Neurol.* 2006; 2:482–493. [PubMed: 16932613]
- Ferenci P. Wilson's disease. *Clin Gastroenterol Hepatol.* 2005; 3(8):726–733. [PubMed: 16233999]
- Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. *Hum Genet.* 2006; 120(2):151–159. [PubMed: 16791614]
- Folhoffer A, et al. Novel mutations of the ATP7B gene among 109 Hungarian patients with Wilson's disease. *Eur J Gastroenterol Hepatol.* 2007; 19(2):105–111. [PubMed: 17272994]
- Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. *Nucl Recept.* 2004; 2(1):4. [PubMed: 15312234]
- Gupta A, et al. Molecular pathogenesis of Wilson disease: haplotype analysis, detection of prevalent mutations and genotype-phenotype correlation in Indian patients. *Hum Genet.* 2005; 118(1):49–57. [PubMed: 16133174]
- Hayashi M, et al. Accumulation of copper induces DNA strand breaks in brain cells of Long-Evans Cinnamon (LEC) rats, an animal model for human Wilson Disease. *Exp Anim.* 2006; 55(5):419–426. [PubMed: 17090957]
- Hermann W, et al. Genotype correlation with fine motor symptoms in patients with Wilson's disease. *Eur Neurol.* 2002; 48(2):97–101. [PubMed: 12186999]
- Hoek KS, Kidd GJ, Carson JH, Smith R. hnRNP A2 selectively binds the cytoplasmic transport sequence of myelin basic protein mRNA. *Biochemistry.* 1998; 37:7021–7029. [PubMed: 9578590]
- Huster D. Wilson disease. *Best Pract Res Clin Gastroenterol.* 2010; 24(5):531–539. [PubMed: 20955957]
- Huster D, Weizenegger M, Kress S, Mossner J, Caca K. Rapid detection of mutations in Wilson disease gene ATP7B by DNA strip technology. *Clin Chem Lab Med.* 2004; 42(5):507–510. [PubMed: 15202786]
- Huster D, et al. Consequences of copper accumulation in the livers of the *Atp7b*^{-/-} (Wilson disease gene) knockout mice. *Am J Pathol.* 2006; 168(2):423–434. [PubMed: 16436657]
- Huster D, et al. High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. *J Biol Chem.* 2007; 282(11):8343–8355. [PubMed: 17205981]
- Kasai N, et al. Clinico-pathological studies of LEC rats with hereditary hepatitis and hepatoma in the acute phase of hepatitis. *Lab Anim Sci.* 1990; 40(5):502–505. [PubMed: 2170750]
- Kegley KM, et al. Fulminant Wilson's disease requiring liver transplantation in one monozygotic twin despite identical genetic mutation. *Am J Transplant.* 2010; 10(5):1325–1329. [PubMed: 20346064]
- King A, et al. Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease. *Neuropathology.* 2010; 30(4):408–419. [PubMed: 20102526]
- Klein D, Lichtmannegger J, Finckh M, Summer KH. Gene expression in the liver of Long-Evans cinnamon rats during the development of hepatitis. *Arch Toxicol.* 2003; 77(10):568–575. [PubMed: 14574444]
- Kucinkas L, et al. High frequency of the c.3207C>A (p.H1069Q) mutation in ATP7B gene of Lithuanian patients with hepatic presentation of Wilson's disease. *World J Gastroenterol.* 2008; 14(38):5876–5879. [PubMed: 18855987]
- Kusuda Y, et al. Novel mutations of the ATP7B gene in Japanese patients with Wilson disease. *J Hum Genet.* 2000; 45(2):86–91. [PubMed: 10721669]
- La Fontaine S, et al. Effect of the toxic milk mutation (tx) on the function and intracellular localization of Wnd, the murine homologue of the Wilson copper ATPase. *Hum Mol Genet.* 2001; 10(4):361–370. [PubMed: 11157799]
- Levy E, et al. Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson's disease. *Life Sci.* 2007; 80(16):1472–1483. [PubMed: 17303181]

- Li H, et al. Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements. *J Lipid Res.* 2009; 50(5):820–831. [PubMed: 19141871]
- Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY. Function and regulation of human copper-transporting ATPases. *Physiol Rev.* 2007; 87(3):1011–1046. [PubMed: 17615395]
- Macomber L, Imlay JA. The iron-sulfur clusters of dehydratases are primary intracellular targets of copper toxicity. *Proc Natl Acad Sci USA.* 2009; 106(20):8344–8349. [PubMed: 19416816]
- Mak CM, et al. Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: identification of 17 novel mutations and its genetic heterogeneity. *J Hum Genet.* 2008; 53(1):55–63. [PubMed: 18034201]
- Marquez A, Villa-Trevino S, Gueraud F. The LEC rat: a useful model for studying liver carcinogenesis related to oxidative stress and inflammation. *Redox Rep.* 2007; 12(1):35–39. [PubMed: 17263906]
- Marquez-Quinones A, et al. Proteasome activity deregulation in LEC rat hepatitis: following the insights of transcriptomic analysis. *OMICS.* 2007; 11(4):367–384. [PubMed: 18092909]
- McElwee MK, Song MO, Freedman JH. Copper activation of NF-kappaB signaling in HepG2 cells. *J Mol Biol.* 2009; 393(5):1013–1021. [PubMed: 19747488]
- Mercado PA, Ayala YM, Romano M, Buratti E, Baralle FE. Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. *Nucleic Acids Res.* 2005; 33(18):6000–6010. [PubMed: 16254078]
- Merle U, et al. Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease. *BMC Gastroenterol.* 2010; 10:8. [PubMed: 20082719]
- Morello F, et al. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. *Atherosclerosis.* 2009; 207:38–44. [PubMed: 19426978]
- Muller P, et al. Gene expression profiling of liver cells after copper overload in vivo and in vitro reveals new copper-regulated genes. *J Biol Inorg Chem.* 2007; 12(4):495–507. [PubMed: 17211630]
- Munro TP, et al. Mutational analysis of a heterogeneous nuclear ribonucleoprotein A2 response element for RNA trafficking. *J Biol Chem.* 1999; 274:34389–34395. [PubMed: 10567417]
- Muramatsu Y, et al. The rat homologue of the Wilson's disease gene was partially deleted at the 3' end of its protein-coding region in Long-Evans Cinnamon mutant rats. *Res Commun Mol Pathol Pharmacol.* 1995; 89(3):421–424. [PubMed: 8680810]
- Nair J, et al. Lipid peroxidation-induced etheno-DNA adducts in the liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis. *Cancer Epidemiol Biomarkers Prev.* 1998; 7(5):435–440. [PubMed: 9610794]
- Nicastro E, et al. Genotype-phenotype correlation in Italian children with Wilson's disease. *J Hepatol.* 2009; 50(3):555–561. [PubMed: 19118915]
- Okada T, et al. High prevalence of fulminant hepatic failure among patients with mutant alleles for truncation of ATP7B in Wilson's disease. *Scand J Gastroenterol.* 2010; 45(10):1232–1237. [PubMed: 20491539]
- Park HD, Ki CS, Lee SY, Kim JW. Carrier frequency of the R778L, A874V, and N1270S mutations in the ATP7B gene in a Korean population. *Clin Genet.* 2009; 75(4):405–407. [PubMed: 19419418]
- Peebles KA, Dwyer-Nield LD, Malkinson AM. Altered expression of splicing factor, heterogeneous nuclear ribonucleoprotein A2/B1, in mouse lung neoplasia. *Mol Carcinog.* 2007; 46(11):887–900. [PubMed: 17477362]
- Petrushin K, et al. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. *Hum Mol Genet.* 1994; 3(9):1647–1656. [PubMed: 7833924]
- Phinney AL, et al. In vivo reduction of amyloid-beta by a mutant copper transporter. *Proc Natl Acad Sci USA.* 2003; 100(24):14193–14198. [PubMed: 14617772]
- Platonova NA, et al. In vivo expression of copper transporting proteins in rat brain sections. *Izv Akad Nauk Ser Biol.* 2005; 2:141–154. Trans from Rus. in Russian.
- Raju CS, et al. In cultured oligodendrocytes the A/B-type hnRNP CBF-A accompanies MBP mRNA bound to mRNA trafficking sequences. *Mol Biol Cell.* 2008; 19:3008–3019. [PubMed: 18480411]

- Ralle M, et al. Wilson disease at a single cell level: intracellular copper trafficking activates compartment-specific responses in hepatocytes. *J Biol Chem*. 2010; 285(40):30875–30883. [PubMed: 20647314]
- Roberts EA, Robinson BH, Yang S. Mitochondrial structure and function in the untreated Jackson toxic milk (tx-j) mouse, a model for Wilson disease. *Mol Genet Metab*. 2008; 93(1):54–65. [PubMed: 17981064]
- Santos EM, et al. Identifying health impacts of exposure to copper using transcriptomics and metabolomics in a fish model. *Environ Sci Technol*. 2010; 44(2):820–826. [PubMed: 20020678]
- Shan J, et al. Binding of an RNA trafficking response element to heterogeneous nuclear ribonucleoproteins A1 and A2. *J Biol Chem*. 2000; 275(49):38286–38295. [PubMed: 11024030]
- Stapelbroek JM, et al. The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. *J Hepatol*. 2004; 41:758–763. [PubMed: 15519648]
- Tanzi RE, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. *Nat Genet*. 1993; 5(4):344–350. [PubMed: 8298641]
- Theophilus MB, Cox DW, Mercer JF. The toxic milk mouse is a murine model of Wilson disease. *Hum Mol Genet*. 1996; 5(10):1619–1624. [PubMed: 8894697]
- Trocello JM, et al. Corpus callosum abnormalities in Wilson's disease. *J Neurol Neurosurg Psychiatry*. 2010
- Tsubota A, et al. IQGAP1 and vimentin are key regulator genes in naturally occurring hepatotumorigenesis induced by oxidative stress. *Carcinogenesis*. 2010; 31(3):504–511. [PubMed: 20015863]
- Voskoboinik I, Greenough M, La Fontaine S, Mercer JF, Camakaris J. Functional studies on the Wilson copper P-type ATPase and toxic milk mouse mutant. *Biochem Biophys Res Commun*. 2001; 281(4):966–970. [PubMed: 11237756]
- Vrabelova S, Letocha O, Borsky M, Kozak L. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. *Mol Genet Metab*. 2005; 86(1–2):277–285. [PubMed: 15967699]
- Wilson AM, Schlade-Bartusiak K, Tison JL, Macintyre G, Cox DW. A minigene approach for analysis of ATP7B splice variants in patients with Wilson disease. *Biochimie*. 2009; 91(10):1342–1345. [PubMed: 19540904]
- Wu ZY, et al. Mutation analysis and the correlation between genotype and phenotype of Arg778Leu mutation in Chinese patients with Wilson disease. *Arch Neurol*. 2001; 58(6):971–976. [PubMed: 11405812]
- Wu S, et al. hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung. *Lung Cancer*. 2003; 41(2):179–186. [PubMed: 12871781]
- Yasuda J, et al. Reactive oxygen species modify oligosaccharides of glycoproteins in vivo: a study of a spontaneous acute hepatitis model rat (LEC rat). *Biochem Biophys Res Commun*. 2006; 342(1):127–134. [PubMed: 16480686]
- Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. *J Endocrinol*. 2010; 204(3):233–240. [PubMed: 19837721]

Fig. 1.

The top 10 canonical signaling pathways down-regulated in LEC rats (*top*) and Atp7b^{-/-} mice (*bottom*). Differentially expressed genes (greater than 1.5 fold) were derived from comparing 6-week old Atp7b^{-/-} to wild-type littermates; or 26 week old LEC rats—to 4 week old LEC rats. Ingenuity Pathway Analysis (IPA) defined 218 genes from Atp7b^{-/-} and 1208 from LEC rats eligible for pathway analysis. These genes were queried against the IPA pathway library to identify over-represented signaling pathways that were significantly down-regulated. The significance [-log (P-value)] of a given pathway is measured by the likelihood that the pathway is associated with the dataset by random chance using the Fischer's exact test. *Striped bars* Pathways common to Atp7b^{-/-} mice and LEC rats. *Black bars* Pathways unique to Atp7b^{-/-} mice or LEC rats. *Pathways involved in lipid or steroid metabolism

Fig. 2. The most populated network of genes up-regulated in 6 week old *Atp7b*^{-/-} mice as defined by Ingenuity Network analysis. *Shaded symbols* represent transcripts for which the change in abundance was experimentally demonstrated

Animal models for Wilson's disease

Table 1

Name	Mutation	Atp7b synthesis and activity	Phenotype	References
Long-Evans Cinnamon (LEC) rat Parental strain: Long-Evans Agouti (LEA)	Gene deletion removing 900 bp of the 3'-coding region and about 400 bp of 3'UTR The strain contains two other mutations outside of <i>Atp7b</i> gene	The synthesis of the full-length protein and copper transport activity are abrogated	Early copper accumulation in the liver, subsequently in other tissues, significant liver pathology, increased mortality at 4 months, low ceruloplasmin activity, abnormal lipid metabolism, abnormal serotonin <i>N</i> -acetyltransferase activity and coat color	Levy et al. (2007), Muramatsu et al. (1995), Marquez et al. (2007), Kasai et al. (1990)
LPP rat Parental strain: LEC rat	The same deletion as in the LEC rat at the position nt 2110 of the <i>Atp7b</i> intron 15. In this strain the non- <i>Atp7b</i> mutations are corrected	The synthesis of the full-length protein and copper transport activity are abrogated	Normal serotonin <i>N</i> -acetyltransferase activity and coat color, whereas liver phenotype is identical to that of the parental LEC rats	Ahmed et al. (2005)
Toxic milk mice (<i>tx</i>) Mutation first appeared in the DL strain, which was subsequently outcrossed to C57BL/6	Met1386Val mutation in the 8th trans-membrane segment	Protein is produced but the copper transport activity is greatly diminished	Copper accumulation in the liver, spleen, kidney and the brain, morphologic changes in hepatocytes accumulation of microvesicular lipid droplets	Theophilos et al. (1996), Voskoboinik et al. (2001), La Fontaine et al. (2006), Biempica et al. (1988)
Toxic milk mice Jackson <i>lab</i> (<i>txl</i>) C3HeB/FeJ- <i>Atp7b</i> ^{tx-J/J} Parental strain: C3H/HeJ	G > A substitution at the position 2135 in exon 8 of the gene results in Gly ⁷¹² Asp mutation in the second transmembrane segment In addition, Lys ¹⁰⁷ Ser and His ¹⁰⁸ Ala, which are thought to be polymorphisms	Protein expression and activity have not been characterized	Copper accumulation in the liver and at 6 months in the brain, cirrhosis; neuronal necrosis in the dorsal and lateral aspects of the frontal parietal and occipital lobes; infant mice are copper deficient and show high mortality. Fostering with wt dams increases survival	Roberts et al. (2008)
<i>Atp7b</i> ^{-/-} mice Background strain: C57BLx129S6/SvEv	Engineered multiple stop codons in the exon 2	The synthesis of the full-length ATP7B and copper transport activity are abrogated	Early copper accumulation in the liver, later in other organs, marked liver pathology, low ceruloplasmin activity, abnormal lipid metabolism, proliferation of bile ducts	Buiakova et al. (1999), Huster et al. (2006), Ralle et al. (2010), Huster et al. (2007)

Table 2

Cellular processes up-regulated in rodent models of WD

LEC Rat (Tsubota et al.)		LEC Rat (Klein et al.)		Atp7b ^{-/-} mice (Huster et al.)	
Ontology	Z-score	Ontology	Z-score	Ontology	Z-score
<i>Organelle fission</i>	8.2	Cell cycle	4.49	<i>Mitosis</i>	8.57
Cell cycle	8.09	Response to DNA damage stimulus	4.43	<i>Nuclear division</i>	8.57
<i>M phase of mitotic cell cycle</i>	7.82	DNA damage response	4.13	<i>M phase</i>	8.52
<i>Mitosis</i>	7.7	Response to endogenous stimulus	4.03	<i>M phase of mitotic cell cycle</i>	8.48
<i>Nuclear division</i>	7.7	Regulation of cell cycle	4	<i>Organelle fission</i>	8.45
<i>M phase</i>	7.31	Cell cycle process	3.97	Cell cycle phase	8.2
Cell cycle phase	7.13	Response to hormone stimulus	3.69	Cell cycle process	7.93
Mitotic cell cycle	6.94	<i>Morphogenesis</i>	3.6	DNA packaging	7.81
Cell cycle process	6.89	Regulation of biological process	3.51	Cell cycle	7.8
Antigen processing and presentation	6.25	Regulation of cellular process	3.46	Mitotic cell cycle	7.37
Chromosome segregation	6.22	Cell cycle checkpoint	3.34	Chromosome condensation	7.35
Microtubule-based process	6.22	Response to corticosterone	3.34	DNA conformation change	7.11
<i>Cell division</i>	6.06	DNA replication	3.32	Mitotic cell cycle checkpoint	7.11
Regulation of cell cycle	5.46	Bone development	3.25	<i>Cell division</i>	6.99
Response to stress	5.35	Ossification	3.25	Cell cycle checkpoint	6.63
Response to stimulus	5.26	Cell growth	3.23	DNA damage checkpoint	6.49
Cytoskeleton organization	5.2	Sexual reproduction	3.19	Reciprocal meiotic recombination	6.22
Cell death	5.19	Gland morphogenesis	3.17	DNA integrity checkpoint	6.15
Microtubule-based movement	5.19	Cell cycle phase	3.14	Response to copper ion	5.9
<i>Morphogenesis</i>	5.16	Response to organic substance	3.13	Synaptic vesicle endocytosis	5.9
Cellular component organization	5.12	Mitotic cell cycle	3.1	Regulation of natural killer cell	4.95
Mitotic sister chromatid segregation	5.1	Cellular response to stress	3.09	Regulation of cell cycle	4.94

Top 22 enriched gene ontology terms are shown; similar processes are differentiated in *bold/italics* fonts; *bold emphasis* indicates processes upregulated in all three cases; *italics emphasis* shows processes upregulated in 2 out of 3 models

Table 3

Cellular processes down-regulated in the rodent models of WD

LEC Rat (Tsubota et al.)		LEC Rat (Klein et al.)		Atp7b ^{-/-} mice (Huster et al.)	
Ontology	Z-score	Ontology	Z-score	Ontology	Z-score
Triglyceride metabolism	8.78	<i>Oxidation reduction</i>	4.16	Cholesterol biosynthetic process	21.72
Monocarboxylic acid metabolic process	8.56	Renal system process	4.02	Sterol biosynthesis	21.5
Lipid metabolism	8.55	Hormone metabolism	3.19	Steroid biosynthesis	18.25
<i>Cholesterol metabolism</i>	8.5	Activation of pro-apoptotic genes	3.08	<i>Sterol metabolism</i>	17.18
<i>Organic ether metabolic process</i>	8.4	Steroid metabolism	3	<i>Cholesterol metabolism</i>	16.84
Steroid metabolism	8.35	Aromatic compound metabolic process	2.92	Steroid metabolism	14.81
Acylglycerol metabolism	8.29	Hormone metabolism	2.81	Lipid metabolism	12.97
Neutral lipid metabolic process	8.29	Lipid metabolism	2.74	Isoprenoid biosynthetic process	12.92
<i>Carboxylic acid metabolism</i>	8.1	Regulation of hormone levels	2.65	Lipid biosynthesis	12.36
Oxoacid metabolic process	8.1	Immunoglobulin production	2.55	Isoprenoid metabolism	11.14
<i>Sterol metabolism</i>	8.09	Aromatic compound catabolic process	2.36	Alcohol metabolism	10.12
Organic acid metabolism	8.03	C21-steroid hormone metabolic process	2.36	<i>Cellular lipid metabolism</i>	10.02
Glycerol ether metabolism	7.96	Estrogen metabolism	2.36	Monocarboxylic acid metabolism	9.48
Ketone metabolism	7.89	Glycerophospholipid metabolism	2.36	<i>Fatty acid metabolism</i>	8.85
Lipid homeostasis	7.85	<i>Organic ether metabolic process</i>	2.36	Positive regulation of lipid biosynthesis	8.21
<i>Fatty acid metabolism</i>	7.65	Glycerolipid metabolic process	2.17	<i>Regulation cholesterol metabolism</i>	8.2
Regulation of cellular ketone metabolism	7.57	Lymphocyte apoptosis	2.17	Small molecule metabolism	8.1
<i>Cholesterol metabolism regul.</i>	7.24	Mediators of immune response	2.13	Carboxylic acid biosynthesis	8.03
Triglyceride biosynthetic process	6.9	Benzene derivatives metabolism	2.02	Organic acid biosynthesis	8.03
Positive regulation of fatty acid metabolism	6.89	Dendrite morphogenesis	2.02	<i>Carboxylic acid metabolism</i>	7.39
<i>Lipid metabolism</i>	6.86	Metabolic process	2.01	<i>Oxidation reduction</i>	7.39

Similar processes are differentiated in *bold/italics fonts*; *bold emphasis* indicates processes upregulated in all three cases; *italics emphasis* shows processes upregulated in 2 out of 3 models